Powering Inclusive, Data Driven Clinical Trials in the UK In Line with Evolving Regulatory Guidance

In December 2025, the U.S. FDA issued new guidance on enhancing participation in clinical trials, placing clear emphasis on broader eligibility criteria, representative enrolment, and removal of avoidable participation barriers. Concurrently, ICH E6(R3) modernised Good Clinical Practice, introducing a principle based, risk proportionate framework centred on quality by design and early stakeholder engagement. 

Together, these developments signal a structural change in how clinical trials are evaluated. Regulators are no longer focused solely on protocol compliance. They are increasingly scrutinising whether studies are feasible in real world settings and whether enrolled populations reflect intended use. 

For sponsors, this raises a strategic question. Is your delivery model built for where regulation is going, or where it has been?  

From Regulatory Expectation to Operational Execution 

The FDA now expects sponsors to justify restrictive eligibility criteria and demonstrate that enrolment strategies support broader participation. ICH E6(R3) reinforces that quality must be embedded at the design stage, with proportional oversight and stakeholder input shaping operational planning. 

This elevates site strategy from an operational consideration to a board level risk variable. Delayed recruitment, protocol amendments, and unrepresentative populations are no longer simply execution challenges. They carry regulatory, commercial, and reputational consequences. 

Sponsors need infrastructure that can deliver representativeness, feasibility, and quality simultaneously.  

The EMS Healthcare Advantage 

EMS Healthcare operates a UK wide community site network designed specifically to meet this new regulatory and commercial environment. 

Our flexible model is strategically engineered rather than reactive. Before the first patient is screened, we deploy our proprietary LASER feasibility system alongside advanced data driven recruitment analytics to identify optimal geographic locations for each study. This ensures that sites are positioned where eligible patient populations genuinely exist, significantly reducing recruitment risk and accelerating activation timelines. 

This approach enables: 

By embedding research capability within communities, we unlock patient populations that are frequently underrepresented while maintaining full GCP compliance and inspection readiness.